Circulating tumor DNA (ctDNA) studies, in cases of acquired resistance to anti-EGFR therapies, have allowed the identification of genomic alterations such as RAS and other molecular drivers, in tumors initially diagnosed as wild type (WT) [114]. This evidence concerns the gene EGFR and neoplasm.